Serotonin metabolite excretion after postmenopausal estradiol therapy

Lippert, T. H.; Filshie, Marcus; Mück, A. O.; Seeger, Harald; Zwirner, M.

doi:10.1016/0378-5122(95)00998-1

Cited by 47 publications

(17 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In vitro experiments have demonstrated that E 2 is able to significantly enhance serotonin uptake in human thrombocytes [37]. Comparing oral and transdermal ERT we found a positive effect for both oral and transdermal E 2 after 2 and 4 weeks' treatment, which was more pronounced for transdermal ERT [38].…”

Section: Effects Of Estrogensmentioning

confidence: 76%

Biochemical markers surrogating on vascular effects of sex steroid hormones

Mueck

Seeger

2006

Gynecological Endocrinology

Self Cite

View full text Add to dashboard Cite

The main mechanism of possible cardioprotection by estrogens appears to be a direct effect on the vasculature, resulting in an improvement of endothelial function and inhibition of atherogenesis. Numerous observational and experimental studies have demonstrated a positive correlation between estrogens and various biochemical markers surrogating direct vascular effects. In general, most markers are influenced in a similar way by oral and transdermal hormone therapy, although oral therapy may have a faster and more pronounced effect. The main difference between oral and transdermal administration may be confined to markers that are mainly or exclusively produced in the liver. Clinical studies demonstrate that progestogen addition can have an impact on the beneficial estrogen-induced changes of biochemical markers. Concerning the effects of tibolone, inconsistent data have been found. Overall, tibolone-induced beneficial changes on the various biochemical markers appear to be less marked compared with those of hormone therapy. The few data available on the direct effects of androgens on the vascular wall indicate a less favorable action of androgens on biochemical markers than of estrogens. The practical relevance of marker measurements is currently under discussion. Although evidence strongly supports some of these markers as predictors of acute events, it remains to be established whether modifying circulating levels of these markers will influence outcomes.

show abstract

Section: Effects Of Estrogensmentioning

confidence: 76%

Biochemical markers surrogating on vascular effects of sex steroid hormones

Mueck

Seeger

2006

Gynecological Endocrinology

Self Cite

View full text Add to dashboard Cite

show abstract

“…In spontaneous and surgically menopausal women, it was found that blood levels of 5-HT were reduced by about 50% when compared to premenopausal controls and oestrogen replacement restored levels to normal [24]. Further, oestrogen replacement in postmenopausal women augmented serotonergic activity, and increased the excretion of 5HIAA [25], and increased the expression of tryptophan hydroxylase, the key enzyme in serotonin biosynthesis [23]. In addition, a number of serotonergic compounds such as 5-HT re-uptake inhibitors fluoxetine, venlafaxine, sertraline and paroxetine, and the 5-HT antagonists mianserin and mirtazapine were shown to reduce both the number and intensity of hot flushes.…”

Section: Discussionmentioning

confidence: 97%

Folic acid supplementation may cure hot flushes in postmenopausal women: a prospective cohort study

Gaweesh

Abd-ElGawad

Nagaty

et al. 2010

Gynecological Endocrinology

View full text Add to dashboard Cite

show abstract

“…A study to determine the effect of transdermal and oral estradiol on serotonin metabolism measured the urinary serotonin metabolite 5-hydroxyindole acetic acid (5-HIAA) after 2 and 4 weeks of estradiol treatment in postmenopausal women, and showed that estradiol produced a signifi cant increase in 5-HIAA [38]. However, compared with the oral route, serotonin turnover was more effectively induced by the consistent and continuous low delivery associated with the transdermal route of delivery.…”

Section: Hormone Replacement Therapymentioning

confidence: 98%

Migraine headache in perimenopausal and menopausal women

MacGregor

2009

Current Science Inc

View full text Add to dashboard Cite

Perimenopause marks a time of change in a woman's hormonal environment, which is apparent from the resultant irregular periods and vasomotor symptoms. These symptoms can start in the early 40s and continue through to the early 50s. Migraine is also affected by hormonal fluctuations, particularly the natural decline in estrogen in the late luteal phase of the menstrual cycle. This effect of estrogen "withdrawal" on migraine appears to become more predominant during perimenopause. Despite the increased prevalence of headache and migraine in women in their 40s, migraine is underdiagnosed in this population. In women attending with symptoms suggestive of perimenopause, it is important to ask about headache symptoms. Once diagnosed, a number of strategies can be used to manage both perimenopausal migraine and menopausal symptoms effectively, with the potential to reduce the associated morbidity.

show abstract

Serotonin metabolite excretion after postmenopausal estradiol therapy

Cited by 47 publications

References 11 publications

Biochemical markers surrogating on vascular effects of sex steroid hormones

Biochemical markers surrogating on vascular effects of sex steroid hormones

Folic acid supplementation may cure hot flushes in postmenopausal women: a prospective cohort study

Migraine headache in perimenopausal and menopausal women

Contact Info

Product

Resources

About